CFTR inhibition mimics the cystic fibrosis inflammatory profile.
Primary airway epithelial cells grown in air-liquid interface differentiate into cultures that resemble native epithelium morphologically, express ion transport similar to those in vivo, and secrete cytokines in response to stimuli. Comparisons of cultures derived from normal and cystic fibrosis (CF) individuals are difficult to interpret due to genetic differences besides CFTR. The recently discovered CFTR inhibitor, CFTR(inh)-172, was used to create a CF model with its own control to test if loss of CFTR-Cl(-) conductance alone was sufficient to initiate the CF inflammatory response. Continuous inhibition of CFTR-Cl(-) conductance for 3-5 days resulted in significant increase in IL-8 secretion at basal (P = 0.006) and in response to 10(9) Pseudomonas (P = 0.0001), a fourfold decrease in Smad3 expression (P = 0.02), a threefold increase in RhoA expression, and increased NF-kappaB nuclear translocation upon TNF-alpha/IL-1beta stimulation (P < 0.000001). CFTR inhibition by CFTR(inh)-172 over this period does not increase epithelial sodium channel activity, so lack of Cl(-) conductance alone can mimic the inflammatory CF phenotype. CFTR(inh)-172 does not affect IL-8, IL-6, or granulocyte/macrophage colony-stimulating factor secretion in two CF phenotype immortalized cell lines: 9/HTEo(-) pCEP-R and 16HBE14o(-) AS, or IL-8 secretion in primary CF cells, and inhibitor withdrawal abolishes the increased response, so CFTR(inh)-172 effects on cytokines are not direct. Five-day treatment with CFTR(inh)-172 does not affect cells deleteriously as evidenced by lactate dehydrogenase, trypan blue, ciliary activity, electron micrograph histology, and inhibition reversibility. Our results support the hypothesis that lack of CFTR activity is responsible for the onset of the inflammatory cascade in the CF lung.
Perez
Aura
A
Department of Pediatrics, School of Medicine, Case Western Reserve University, BRB Bldg. R829, 10900 Euclid Ave., Cleveland, OH 44106-4948, USA. aura.perez@case.edu
Issler
Amanda C
AC
Cotton
Calvin U
CU
Kelley
Thomas J
TJ
Verkman
Alan S
AS
Davis
Pamela B
PB
D000584:Amiloride / Q000494:pharmacology; D002454:Cell Differentiation / Q000187:drug effects; D002467:Cell Nucleus / Q000187:drug effects; D003550:Cystic Fibrosis / Q000378:metabolism / Q000473:pathology*; D019005:Cystic Fibrosis Transmembrane Conductance Regulator / Q000037:antagonists & inhibitors* / Q000378:metabolism; D016207:Cytokines / Q000096:biosynthesis / Q000378:metabolism; D004553:Electric Conductivity; D004847:Epithelial Cells / Q000166:cytology / Q000187:drug effects / Q000648:ultrastructure; D006801:Humans; D007249:Inflammation / Q000378:metabolism / Q000473:pathology; D018716:Molecular Mimicry / Q000187:drug effects*; D050505:Mutant Proteins / Q000494:pharmacology*; D021381:Protein Transport / Q000187:drug effects; D051900:Smad3 Protein / Q000378:metabolism; D051996:Transcription Factor RelA / Q000378:metabolism; D020742:rhoA GTP-Binding Protein / Q000378:metabolism
D016207:Cytokines; D050505:Mutant Proteins; D051900:Smad3 Protein; D051996:Transcription Factor RelA; D019005:Cystic Fibrosis Transmembrane Conductance Regulator; D000584:Amiloride; D020742:rhoA GTP-Binding Protein